AJP - Heart Ad Instruments
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 288: H461-H468, 2005; doi:10.1152/ajpheart.00402.2004
0363-6135/05 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lovelock, J. D.
Right arrow Articles by Mann, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lovelock, J. D.
Right arrow Articles by Mann, D. L.

Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts

Joshua D. Lovelock,1 Andrew H. Baker,2 Feng Gao,1 Jing-Fei Dong,3 Angela L. Bergeron,3 Willie McPheat,4 Natarajan Sivasubramanian,1 and Douglas L. Mann1

1Winters Center for Heart Failure Research, Michael E. DeBakey Department of Veterans Affairs Medical Center, and 3Thrombosis Section, Baylor College of Medicine and Methodist Hospital, Houston, Texas; 2Division of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; and 4Molecular Pharmacology Department, AstraZeneca R&D Molndal, AstraZeneca Pharmaceuticals, Gothenburg, Sweden

Submitted 29 April 2004 ; accepted in final form 11 August 2004

The balance between matrix metalloproteinases (MMPs) and their natural inhibitors, the tissue inhibitors of metalloproteinases (TIMPs), plays a critical role in cardiac remodeling. Although a number of studies have characterized the pathophysiological role of MMPs in the heart, very little is known with respect to the role of TIMPs in the heart. To delineate the role of TIMPs in the heart we examined the effects of adenovirus-mediated overexpression of TIMP-1, -2, -3, and -4 in cardiac fibroblasts. Infection of cardiac fibroblasts with adenoviral constructs containing human recombinant TIMP (AdTIMP-1, -2, -3, and -4) provoked a significant (P < 0.0001) 1.3-fold in increase in bromodeoxyuridine (BrdU) incorporation. Similarly, treatment of cardiac fibroblasts with AdTIMP-1-, -2-, -3-, and -4-conditioned medium led to a 1.2-fold increase in BrdU incorporation (P < 0.0001) that was abolished by pretreatment with anti-TIMP-1, -2, -3, and -4 antibodies. The effects of TIMPs were not mimicked by treating the cells with RS-130830, a broad-based MMP inhibitor, suggesting that the effects of TIMPs were independent of their ability to inhibit MMPs. Infection with AdTIMP-1, -2, -3, and -4 led to a significant increase in {alpha}-smooth muscle actin staining, consistent with TIMP-induced phenotypic differentiation into myofibroblasts. Finally, infection with AdTIMP-2 resulted in a significant increase in collagen synthesis, whereas infection with AdTIMP-3 resulted in a significant increase in fibroblast apoptosis. TIMPs exert overlapping as well as diverse effects on isolated cardiac fibroblasts. The observation that TIMPs stimulate fibroblast proliferation as well as phenotypic differentiation into myofibroblasts suggests that TIMPs may play an important role in tissue repair in the heart that extends beyond their traditional role as MMP inhibitors.

matrix metalloproteinase; proliferation; apoptosis; phenotypic differentiation



Address for reprint requests and other correspondence: D. L. Mann, Winters Center for Heart Failure Research, MS 524, 6565 Fannin, Houston, TX 77030 (E-mail:dmann{at}bcm.tmc.edu)




This article has been cited by other articles:


Home page
CirculationHome page
J. A. Dixon, R. C. Gorman, R. E. Stroud, S. Bouges, H. Hirotsugu, J. H. Gorman III, T. P. Martens, S. Itescu, M. D. Schuster, T. Plappert, et al.
Mesenchymal Cell Transplantation and Myocardial Remodeling After Myocardial Infarction
Circulation, September 15, 2009; 120(11_suppl_1): S220 - S229.
[Abstract] [Full Text] [PDF]


Home page
Circ Heart FailHome page
F. G. Spinale, G. P. Escobar, R. Mukherjee, J. A. Zavadzkas, S. M. Saunders, L. B. Jeffords, A. M. Leone, C. Beck, S. Bouges, and R. E. Stroud
Cardiac-Restricted Overexpression of Membrane Type-1 Matrix Metalloproteinase in Mice: Effects on Myocardial Remodeling With Aging
Circ Heart Fail, July 1, 2009; 2(4): 351 - 360.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
F. G. Spinale
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
Physiol Rev, October 1, 2007; 87(4): 1285 - 1342.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
D. M. Jaworski, M. Beem-Miller, G. Lluri, and R. Barrantes-Reynolds
Potential regulatory relationship between the nested gene DDC8 and its host gene tissue inhibitor of metalloproteinase-2
Physiol Genomics, January 17, 2007; 28(2): 168 - 178.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
D. Vanhoutte, M. Schellings, Y. Pinto, and S. Heymans
Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window
Cardiovasc Res, February 15, 2006; 69(3): 604 - 613.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2005 by the American Physiological Society.